Table 3.
Days in culture | Treatment (oligonucleotide) | Dose (μM) | Primary minor process length (μm) | % Branched primary minor processes | Primary axon length (μm) | Number of branches/axon |
---|---|---|---|---|---|---|
1 | None | – | 34±1 | 41±4 | – | – |
1 | Sense Ror1+Sense Ror2 | 50 | 35±2 | 39±4 | – | – |
1 | Antisense Ror1+Antisense Ror2 | 50 | 27±1* | 24±3* | – | – |
2 | None | - | 37±2 | 57±4 | 107±5 | 2.7±0.2 |
2 | Sense Ror1+Sense Ror2 | 50 | 31±2 | 50±4 | 112±3 | 2.2±0.2 |
2 | Antisense Ror1+Antisense Ror2 | 50 | 26±1* | 30±2* | 165±8* | 1.9±0.2† |
E16 hippocampal cultures were plated at 75,000 cells/dish and allowed to develop for 1 (stage II) or 2 (stage III) days. Cells were fixed and stained with a tubulin antibody (clone DMIA). Neuritic processes from randomly selected cells were viewed by phase-contrast microscopy using a digital camera and traced onscreen. Neuritic length was determined using Metamorph Image Analysis Software. Forty cells from three independent experiments were analyzed for each condition. Results are expressed as mean±s.e.m.
P<0.01 compared to all controls;
P<0.01 compared to untreated controls.